Chemistry:Lumiliximab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (primate/human) |
| Target | CD23 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C2115H3252N556O673S16 |
| Molar mass | 47749.46 g·mol−1 |
  (what is this?) (verify) | |
Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator[1] and was awarded orphan drug status and fast track designation by the FDA.[2]
It was investigated in Phase II/III clinical trials for the treatment of chronic lymphocytic leukemia.[3][4] It has also been studied for use in allergic asthma. The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]
Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.[2] Results published from the CLL clinical trial failed to meet primary endpoints.[5]
References
- ↑ 1.0 1.1 "International Nonproprietary Names for Pharmaceutical Substances (INN)". WHO Drug Information 18 (3). 2004. https://www.who.int/medicines/publications/druginformation/innlists/RL52.pdf?ua=1.
- ↑ 2.0 2.1 "Lumiliximab". Adis Insight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800008890.
- ↑ "Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia". Blood 115 (3): 489–95. January 2010. doi:10.1182/blood-2009-08-237727. PMID 19843887.
- ↑ Clinical trial number NCT00801060 for "Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)" at ClinicalTrials.gov
- ↑ "A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia". British Journal of Haematology 167 (4): 466–77. November 2014. doi:10.1111/bjh.13061. PMID 25130401.
 |  |
